HUNTER REED: Open Payments
NPI 1356926992 · SLIDELL, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$636 in 35 payments from 12 companies in 2025. Trend: 2023 $758 · 2024 $597 · 2025 $636
Food & beverage: $636
| Company | Payments | Amount |
|---|---|---|
| Axsome Therapeutics, Inc. | 5 | $104 |
| Novo Nordisk Inc | 6 | $95 |
| GlaxoSmithKline, LLC. | 3 | $62 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $62 |
| Lilly USA, LLC | 3 | $61 |
| Vanda Pharmaceuticals Inc. | 3 | $53 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $51 |
| Lundbeck LLC | 3 | $48 |
| AstraZeneca Pharmaceuticals LP | 2 | $39 |
| Ardelyx, Inc. | 2 | $29 |
Products named: Auvelity, TRELEGY ELLIPTA, TRINTELLIX, MOUNJARO, CAPLYTA, REXULTI, FANAPT, Rybelsus.
Industry payments across LA — which companies pay providers there.
